Mark Reisenauer
Präsident bei IVERIC BIO, INC.
Profil
Mark L.
Reisenauer is currently the President, Secretary, Treasurer & Director at IVERIC bio, Inc. since 2023.
He is also currently the President at Astellas Pharma US, Inc. since 2011.
Previously, he worked as an Associate Director-Oncology Global Marketing at Bristol Myers Squibb Co. from 1997 to 1999.
He then served as the Director-Breast Cancer Products at Pharmacia Corp.
in 1999.
From 2002 to 2007, he held the position of Divisional Vice President at Abbott Laboratories.
Lastly, from 2007 to 2011, he worked as the Chief Commercial Officer & Senior Vice President at Amgen Rockville, Inc. Mr. Reisenauer completed his undergraduate degree at the University of Wisconsin.
Aktive Positionen von Mark Reisenauer
| Unternehmen | Position | Beginn |
|---|---|---|
| IVERIC BIO, INC. | Präsident | 11.07.2023 |
Astellas Pharma US, Inc.
 Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Präsident | 04.02.2021 |
Ehemalige bekannte Positionen von Mark Reisenauer
| Unternehmen | Position | Ende |
|---|---|---|
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Corporate Officer/Principal | 15.04.2011 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01.09.2007 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | 01.01.2002 |
| BRISTOL-MYERS SQUIBB COMPANY | Vertrieb & Marketing | 01.01.1999 |
Ausbildung von Mark Reisenauer
| University of Wisconsin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Astellas Pharma US, Inc.
Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
